SunRock participated in UEG Week 2025, held in Berlin from October 4 to 7, where our collaborator Dr. Manuel Barreiro, Head of the IBD unit of the University Hospital of Santiago de Compostela presented our poster entitled:
“PP0371: SRB3 demonstrates robust ex vivo efficacy in bio-exposed IBD patients and correlates with disease activity.”
The reception was very positive, highlighting both the scientific quality of the data and the interest generated within the international community. These results strengthen the role of anti-CCR9 antibodies as highly promising candidates for the treatment of inflammatory bowel diseases and reinforce SunRock’s position as a leader in biomedical innovation.
